

# Piccolo<sup>®</sup> MetLyte 8 Panel



**For In Vitro Diagnostic Use and Healthcare Professional Use Only**

**Customer and Technical Service: 1- 800-822-2947**

**Customers outside the US: +49 6155 780 210**

[AB-PiccoloTechSupport@zoetis.com](mailto:AB-PiccoloTechSupport@zoetis.com)

**Applicable to US customers only**

**CLIA Waived: Use lithium heparin whole blood, only**

**Moderate Complexity: Use lithium heparin whole blood, lithium heparin plasma, or serum**



Abaxis, Inc.  
3240 Whipple Rd.  
Union City, CA 94587  
USA



Tao of Excellence GmbH  
Vorstadt 26,  
8200 Schaffhausen  
Switzerland



ABAXIS Europe GmbH  
Bunsenstr. 9-11  
64347 Griesheim  
Germany

## 1. Intended Use

The Piccolo<sup>®</sup> MetLyte 8 Panel, used with the Piccolo Xpress<sup>®</sup> chemistry analyzer, is intended to be used for the *in vitro* quantitative determination of chloride, creatine kinase, creatinine, glucose, potassium, sodium, total carbon dioxide and blood urea nitrogen (BUN) in heparinized whole blood, heparinized plasma, or serum in a clinical laboratory setting or point-of-care location/ near patient testing.

### **For US Customers Only**

The tests on this panel are waived under CLIA '88 regulations. If a laboratory modifies the test system instructions, then the tests are considered high complexity and subject to all CLIA requirements. For CLIA waived labs, only lithium heparin whole blood may be tested. For use in moderate complexity labs, lithium heparinized whole blood, lithium heparinized plasma, or serum may be used.

A CLIA Certificate of Waiver is needed to perform CLIA waived testing. A Certificate of Waiver can be obtained from the Centers for Medicare & Medicaid Services (CMS).

## 2. Summary and Explanation of Tests

The Piccolo MetLyte 8 Panel and the Piccolo Xpress chemistry analyzer comprise an *in vitro* diagnostic system that aids the physician in diagnosing the following disorders in adults:


Chloride:	General metabolic diseases, for example, Dehydration, prolonged diarrhea and vomiting, renal tubular disease, hyperparathyroidism, burns, salt-losing renal diseases, overhydration and thiazide therapy.
Creatine Kinase:	Muscle disease, for example, progressive muscular dystrophy, dermatomyositis, rhabdomyolysis due to drug ingestion, hyperosmolality, autoimmune disease, delirium tremens, convulsions, Crush syndrome, hypothyroidism, surgery, severe exercise, intramuscular injection.
Creatinine:	Renal disease and renal dialysis.
Glucose:	Carbohydrate metabolism disorders, for example, adult and juvenile diabetes mellitus and hypoglycemia, hypopituitarism, pancreatitis, and renal disease.
Potassium:	Renal, endocrine, and metabolic disease as well as iatrogenic causes, for example, Renal glomerular or tubular disease, adrenocortical insufficiency, diabetic ketacidosis, excessive intravenous potassium therapy, sepsis, panhypopituitarism, <i>in vitro</i> hemolysis, hyperaldosteronism, malnutrition, hyperinsulinism, metabolic alkalosis and gastrointestinal loss.
Sodium:	Metabolic diseases, for example, Dehydration, diabetes insipidus, loss of hypotonic gastrointestinal fluids, salt poisoning, selective depression of sense of thirst, skin losses, burns, sweating, hyperaldosteronism, CNS disorders, dilutional, depletion and delusional hyponatremia and syndrome of inappropriate ADH secretion.
Total Carbon Dioxide:	Metabolic disorders, for example, metabolic alkalosis and acidosis and primary respiratory alkalosis and acidosis.
Blood urea nitrogen (BUN):	Renal and metabolic diseases.

As with any diagnostic test procedure, all other test procedures including the clinical status of the patient, should be considered prior to final diagnosis.

### 3. Principle of Method

#### Chloride (CL<sup>-</sup>)

The method is based on the determination of chloride-dependent activation of  $\alpha$ -amylase activity. Deactivated  $\alpha$ -amylase is reactivated by addition of the chloride ion, allowing the calcium to re-associate with the enzyme. The reactivation of  $\alpha$ -amylase activity is proportional to the concentration of chloride ions in the sample. The reactivated  $\alpha$ -amylase converts the substrate, 2-chloro-*p*-nitrophenyl- $\alpha$ -D-maltotrioxide (CNPG3) to 2-chloro-*p*-nitrophenol (CNP) producing color and  $\alpha$ -maltotriose (G3). The reaction is measured bichromatically and the increase in absorbance is directly proportional to the reactivated  $\alpha$ -amylase activity and the concentration of chloride ion in the sample.<sup>1</sup>




#### Creatine Kinase (CK)

Creatine kinase catalyzes the reversible phosphorylation of creatine by adenosine triphosphate (ATP). The phosphorylation reaction is favored by alkaline conditions (optimum at pH 9.0) and the dephosphorylation reaction is favored by acidic conditions (optimum at pH 6.5 at 37°C). Early CK measurement methods were based on the "forward reaction" with creatine phosphate and adenosine diphosphate (ADP) as the products.<sup>2,3,4</sup> The sensitivity of these tests was shown to be low due to problems with interferences. The procedure of choice utilizes the "reverse reaction" coupled with a reaction to produce NADPH, which is directly related to CK levels.<sup>5,6,7</sup>

The CK measurement procedure used by Abaxis is a modified version of the International Federation of Clinical Chemistry (IFCC) method.<sup>8</sup> Key modifications are sample volume fraction, buffer, and temperature. N-acetyl cysteine (NAC) has been added to reactivate the CK.<sup>9</sup> Magnesium is used as a cofactor for both CK and hexokinase. EDTA has been added as a stabilizer for NAC and for the removal of various cations, such as calcium and iron, that inhibit CK. P<sup>1</sup>, P<sup>5</sup>-di (adenosine-5')penta phosphate and adenosine monophosphate (AMP) have also been added to inhibit adenylate kinase, another skeletal muscle and erythrocyte enzyme that reacts with the substrates used to measure CK.


Creatine kinase catalyzes the formation of creatine and ATP from creatine phosphate and ADP at pH 6.7. With hexokinase as a catalyst, ATP reacts with D-glucose to form ADP and D-glucose-6-phosphate (G-6-P), which is reacted with nicotinamide adenine dinucleotide phosphate (NADP) in the presence of glucose-6-phosphate dehydrogenase (G-6-PDH) to produce G-6-P and NADPH.




The formation of NADPH is measured as a change in absorbance at 340 nm relative to 405 nm. This absorbance change is directly proportional to creatine kinase activity in the sample.

#### Creatinine (CRE)

The Jaffe method, first introduced in 1886, is still a commonly used method of determining creatinine levels in blood. The current reference method combines the use of Fuller's earth (floridin) with the Jaffe technique to increase the specificity of the reaction.<sup>10,11</sup> Enzymatic methods have been developed that are more specific for creatinine than the various modifications of the Jaffe technique.<sup>12,13,14</sup> Methods using the enzyme creatinine amidohydrolase eliminate the problem of ammonium ion interference found in techniques using creatinine iminohydrolase.<sup>15</sup>





Two cuvettes are used to determine the concentration of creatinine in the sample. Endogenous creatinine is measured in the blank cuvette, which is subtracted from the combined endogenous creatinine and the creatinine formed from the enzyme reactions in the test cuvette. Once the endogenous creatinine is eliminated from the calculations, the concentration of creatinine is proportional to the intensity of the red color produced. The endpoint reaction is measured as the difference in absorbance between 550 nm and 600 nm.

### eGFR (calculated)

Serum creatinine is routinely measured as an indicator of renal function. Because creatinine is influenced by age, gender and race, chronic kidney disease (CKD) may not be detected using serum creatinine alone. Thus, the National Kidney Disease Education Program strongly recommends that laboratories routinely report an estimated Glomerular Filtration Rate (eGFR) when serum creatinine is measured for patients 18 and older. Routinely reporting the eGFR with all serum creatinine determinations allows laboratories to help identify individuals with reduced kidney function and help facilitate the detection of CKD. Calculated eGFR values of <60 ml/min are generally associated with increased risk of adverse outcomes of CKD.


Calculation of the eGFR is performed by the Piccolo using the patient's age, gender and race. The Piccolo method for creatinine is traceable to the IDMS reference method for creatinine so that the following form of the MDRD equation for calculating the eGFR can be used.

$$\text{GFR (mL/min/1.73 m}^2\text{)} = 175 \times (\text{S}_{\text{cr}})^{-1.154} \times (\text{Age})^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if African American})$$

### Glucose (GLU)

Measurements of glucose concentration were first performed using copper-reduction methods (such as Folin-Wu<sup>16</sup> and Somogyi-Nelson<sup>17,18</sup>). The lack of specificity in copper-reduction techniques led to the development of quantitative procedures using the enzymes hexokinase and glucose oxidase. The glucose test incorporated into the Piccolo MetLyte 8 Panel is a modified version of the hexokinase method, which has been proposed as the basis of the glucose reference method.<sup>18,19</sup>


The reaction of glucose with adenosine triphosphate (ATP), catalyzed by hexokinase (HK), produces glucose-6-phosphate (G-6-P) and adenosine diphosphate (ADP). Glucose-6-phosphate dehydrogenase (G-6-PDH) catalyzes the reaction of G-6-P into 6-phosphogluconate and the reduction of nicotinamide adenine dinucleotide (NAD<sup>+</sup>) to NADH.



### Potassium (K<sup>+</sup>)


Spectrophotometric methods have been developed that allow the measurement of potassium concentration on standard clinical chemistry instrumentation. The Abaxis enzymatic method is based on the activation of pyruvate kinase with potassium and shows excellent linearity and negligible susceptibility to endogenous substances.<sup>20,21,22</sup> Interference from sodium and ammonium ion are minimized with the addition of Kryptofix and glutamate dehydrogenase respectively.<sup>20</sup>

In the coupled-enzyme reaction, pyruvate kinase (PK) dephosphorylates phosphoenolpyruvate (PEP) to form pyruvate. Lactate dehydrogenase (LDH) catalyzes conversion of pyruvate to lactate. Concomitantly, NADH is oxidized to NAD<sup>+</sup>. The rate of change in absorbance difference between 340 nm and 405 nm is due to the conversion of NADH to NAD<sup>+</sup> is directly proportional to the amount of potassium in the sample.



### Sodium (NA<sup>+</sup>)


Colorimetric and enzymatic methods have been developed that allow the measurement of sodium concentration on standard clinical chemistry instrumentation.<sup>23,24,25</sup> In the Abaxis enzymatic reaction,  $\beta$ -galactosidase is activated by the sodium in the sample. The activated enzyme catalyzes the reaction of o-nitrophenyl- $\beta$ -D-galactopyranoside (ONPG) to o-nitrophenol and galactose.



### Total Carbon Dioxide (tCO<sub>2</sub>)

Total carbon dioxide in serum or plasma exists as dissolved carbon dioxide, carbamino derivatives of proteins, bicarbonate and carbonate ions and carbonic acid. Total carbon dioxide can be measured by pH indicator, CO<sub>2</sub> electrode and spectrophotometric enzymatic methods, which all produce accurate and precise results.<sup>26,27</sup> The enzymatic method is well suited for use on a routine blood chemistry analyzer without adding complexity.


In the enzymatic method, the specimen is first made alkaline to convert all forms of carbon dioxide (CO<sub>2</sub>) toward bicarbonate (HCO<sub>3</sub><sup>-</sup>). Phosphoenolpyruvate (PEP) and HCO<sub>3</sub><sup>-</sup> then react to form oxaloacetate and phosphate in the presence of phosphoenolpyruvate carboxylase (PEPC). Malate dehydrogenase (MDH) catalyzes the reaction of oxaloacetate and reduced nicotinamide adenine dinucleotide (NADH) to NAD<sup>+</sup> and malate. The rate of change in absorbance due to the conversion of NADH to NAD<sup>+</sup> is directly proportional to the amount of tCO<sub>2</sub> in the sample.



### Blood Urea Nitrogen (BUN)

Urea can be measured both directly and indirectly. The diacetyl monoxime reaction, the only direct method to measure urea, is commonly used but employs dangerous reagents.<sup>28</sup> Indirect methods measure ammonia created from the urea; the use of the enzyme urease has increased the specificity of these tests.<sup>29</sup> The ammonia is quantitated by a variety of methods, including nesslerization (acid titration), the Berthelot technique<sup>30,31</sup> and coupled enzymatic reactions.<sup>32,33</sup> Catalyzed Berthelot procedures, however, are erratic when measuring ammonia.<sup>34</sup> Coupled-enzyme reactions are rapid, have a high specificity for ammonia, and are commonly used. One such reaction has been proposed as a candidate reference method.<sup>35</sup>

In the coupled-enzyme reaction, urease hydrolyzes urea into ammonia and carbon dioxide. Upon combining ammonia with 2-oxoglutarate and reduced nicotinamide adenine dinucleotide (NADH), the enzyme glutamate dehydrogenase (GLDH) oxidizes NADH to NAD<sup>+</sup>.



The rate of change of the absorbance difference between 340 nm and 405 nm is caused by the conversion of NADH TO NAD<sup>+</sup> and is directly proportional to the amount of urea present in the sample.

## 4. Principle of Operation

Refer to the Piccolo Xpress chemistry analyzer Operator's Manual, for the Principles and Limitations of the Procedure.

## 5. Description of Reagents

### Reagents

Each Piccolo MetLyte 8 Panel contains dry test-specific reagent beads (described below). A dry sample blank reagent (comprised of buffer, surfactants, excipients and preservatives) is included in each disc for use in calculating concentrations of chloride (CL<sup>-</sup>), creatine kinase (CK), glucose (GLU), potassium(K<sup>+</sup>), sodium (NA<sup>+</sup>), total carbon dioxide (tCO<sub>2</sub>) and blood urea nitrogen (BUN). A dedicated sample blank is included in the disc to calculate concentrations of creatinine (CRE). Each disc also contains a diluent consisting of surfactants and preservatives.

**Table 1: Reagents**

Component	Quantity/Disc
2, 4, 6-Tribromo-3-hydroxybenzoic acid	188 µg
2-Chloro-4-nitrophenyl-alpha-maltotrioxide (CNPG3)	105 µg
4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]trisosane	86 µg
4-Aminoantipyrine *HCl	24 µg
Adenosine-5'-diphosphate	35 µg
Adenosine-5'-monophosphate	33 µg
Adenosine 5'-diphosphate, monopotassium salt	31 µg
Adenosine 5'-diphosphate, trilithium salt	3.7 µg
Adenosine 5'-triphosphate, disodium salt	12 µg
4-Aminoantipyrine	5.4 µg
Amylase	0.286U
Ascorbate oxidase	0.3 U
Calcium acetate	50.4 µg
Citric acid, trisodium salt	1134 µg
Creatine phosphate	122 µg
3,5-Dichloro-2-hydroxybenzenesulfonic acid , Sodium salt (DHBSA)	34.8 µg
Creatine amidinohydrolase	3 U
Creatinine amidohydrolase	1 U
Ethylene glyco-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)	7 µg
Ethylenediaminetetraacetic acid (EDTA)	11.33 µg
Ethylenediaminetetraacetic acid (EDTA), disodium salt	356 µg
Ethylenediaminetetraacetic acid (EDTA), Tetrasodium Salt	180 µg
Glucose	58 µg
Glucose-6-phosphate dehydrogenase (G6PDH)	0.1 U
Glutamate dehydrogenase	0.01 U
Glutamine synthetase	0.2 U
Hexokinase	0.2 U
Imidazole	26 µg
Lactate dehydrogenase	0.1 U
L-glutamic acid	9 µg
Magnesium acetate, tetrahydrate	68 µg
Magnesium sulfate, heptahydrate	122 µg
Manganese chloride	10 µg
Malate dehydrogenase	0.1 U
N-Acetyl cysteine	75 µg
<i>o</i> -Nitrophenyl-β-D galactopyranoside (ONPG)	44 µg
P1, P5di(adenosine-5')pentaphosphate	0.2 µg
Peroxidase	1 U
Phosphoenol pyruvate	14 µg
Phosphoenol pyruvate carboxylase	0.002 U
Potassium ferrocyanide	0.6 µg
Pyruvate kinase	0.01 U

**Table 1: Reagents (continued)**

Component	Quantity/Disc
Sarcosine oxidase	1 U
β-Nico-tinamide adenine dinucleotide, (NAD)	20 μg
β-Nicotinamide adenine dinucleotide, reduced (NADH)	28 μg
β-Nicotinamide adenine dinucleotide phosphate (NADP+), sodium salt	104 μg
Urease	0.05 U
Uricase	0 U
α-Ketoglutaric acid	18 μg
β-Galactosidase	0.005 U
Buffers, surfactants, excipients and preservatives	

**Warnings and Precautions**

- For *In vitro* Diagnostic Use
- The diluent container in the reagent disc is automatically opened when the analyzer drawer closes. A disc with an opened diluent container can not be re-used. Ensure that the sample or control has been placed into the disc before closing the drawer.
- Used reagent discs contain human body fluids. Follow good laboratory safety practices when handling and disposing of used discs.<sup>36</sup> See the Piccolo Xpress chemistry analyzer Operator's Manual for instructions on cleaning biohazardous spills.
- The reagent discs are plastic and may crack or chip if dropped. **Never** use a dropped disc as it may spray bio-hazards throughout the interior of the analyzer.
- Reagent beads may contain acids or caustic substances. The operator does not come into contact with the reagent beads when following the recommended procedures. In the event that the beads are handled (e.g., cleaning up after dropping and cracking a reagent disc), avoid ingestion, skin contact, or inhalation of the reagent beads.
- This mixture does not contain substances assessed to be vPvB / PBT according to Regulation (EC) No 1907/2006, Annex XIII. This product contains components considered to have endocrine disrupting properties for environment, according to REACH Article 57(f), Regulation (EU) 2018/605 or Regulation (EU) 2017/2100. Refer to the Safety Data Sheet (SDS) for specific details.
- Materials incorporated into the device may consist of substances derived from other microbial and animal sourced materials.

**Instructions for Reagent Handling**

Reagent discs may be used directly from the refrigerator without warming. Do not allow discs sealed in their foil pouches to remain at room temperature at 20-25°C (68-77°F) longer than 48 hours prior to use. Open the sealed foil pouch, remove the disc and use according to the instructions provided in the Piccolo Xpress chemistry analyzer Operator's Manual. A disc not used within 20 minutes of opening the pouch should be discarded.

**Storage**

Store reagent discs in their sealed pouches at 2-8 °C (36-46 °F). Do not expose opened or unopened discs to direct sunlight or temperatures above 32 °C (90 °F). Reagent discs may be used until the expiration date included on the package. The expiration date is also encoded in the bar code printed on the bar code ring. An error message will appear on the Piccolo Xpress chemistry analyzer Display if the reagents have expired.

**Indications of Reagent Disc Instability/Deterioration**

A torn or otherwise damaged pouch may allow moisture to reach the unused disc and adversely affect reagent performance. Do not use a disc from a damaged pouch.

**6. Instrument**

See the Piccolo Xpress chemistry analyzer Operator's Manual for complete information on use of the analyzer.

## 7. Sample Collection and Preparation

Sample collection techniques are described in the “Sample Collection” section of the Piccolo Xpress chemistry analyzer Operator’s Manual.

- The minimum required sample size is ~100 µL of heparinized whole blood, heparinized plasma, serum or control material. The reagent disc sample chamber can contain up to 120 µL of sample.
- Whole blood samples obtained by venipuncture must be homogeneous before transferring a sample to the reagent disc. Gently invert the collection tube several times just prior to sample transfer. Do not shake the collection tube; shaking may cause hemolysis.
- Whole blood samples should only be obtained via venipuncture, not from capillary blood.
- Hemolysis may cause erroneously high results in **potassium** assays. This problem may go undetected when analyzing whole blood (release of potassium from as few as 0.5% of the erythrocytes can increase the potassium serum level by 0.5 mmol/L). In addition, even unhemolyzed specimens that are not promptly processed may have increased potassium levels due to intracellular potassium leakage.<sup>37</sup>
- Whole blood venipuncture samples should be run within 60 minutes of collection.<sup>38</sup>
- Whole blood venipuncture samples should be run within 60 minutes of collection.<sup>38</sup> **Glucose** concentrations are affected by the length of time since the patient has eaten and by the type of sample collected from the patient. To accurately determine glucose results, samples should be obtained from a patient who has been fasting for at least 12 hours. The glucose concentration decreases approximately 5-12 mg/dL in 1 hour in uncentrifuged samples stored at room temperature.<sup>47</sup>
- Refrigerating whole blood samples can cause significant changes in concentration of **creatinine** and **glucose**<sup>39</sup>. The sample may be separated into plasma or serum and stored in capped sample tubes at 2-8 °C (36-46 °F) if the sample cannot be run within 60 minutes.
- Use only lithium heparin evacuated specimen collection tubes for whole blood or plasma samples. Use no-additive evacuated specimen collection tubes or serum separator tubes for serum samples.
- The concentration of **total carbon dioxide** is most accurately determined when the assay is done immediately after opening the tube and as promptly as possible after collection and processing of the blood in the unopened tube. Ambient air contains far less carbon dioxide than does plasma, and gaseous dissolved carbon dioxide will escape from the specimen into the air, with a consequent decrease in carbon dioxide value of up to 6 mmol/L in the course of 1 hour.<sup>40</sup>
- Start the test within 10 minutes of transferring the sample into the reagent disc.

## 8. Procedure

### Materials Provided

- One Piccolo MetLyte 8 Panel PN: 400-1023 (a box of discs PN 400-0023)

### Materials Required but not Provided

- Piccolo Xpress chemistry analyzer
- Sample transfer pipettes (fixed volume approximately 100 µL) and tips are provided with each Piccolo Xpress chemistry analyzer and may be reordered from Abaxis.
- Commercially available control reagents recommended by Abaxis (contact Abaxis Technical Support for approved control materials and expected values).
- Timer

### Test Parameters

The Piccolo Xpress chemistry analyzer operates at ambient temperatures between 15 °C and 32 °C (59-90 °F). The analysis time for each Piccolo MetLyte 8 Panel is less than 14 minutes. The analyzer maintains the reagent disc at a temperature of 37 °C (98.6 °F) over the measurement interval.

### Test Procedure

The complete sample collection and step-by-step operating procedures are detailed in the Piccolo Xpress chemistry analyzer Operator’s Manual.

**Calibration**

The Piccolo Xpress chemistry analyzer is calibrated by the manufacturer before shipment. The bar code printed on the bar code ring provides the analyzer with disc-specific calibration data. See the Piccolo Xpress chemistry analyzer Operator’s Manual.

The Piccolo Xpress chemistry analyzer is calibrated using internal calibrators or reference materials. The methods and materials used in the procedures for the calibration and control value assignments are traceable either to the comparative method and/or to the standards listed below:

- IFCC – International Federation of Clinical Chemistry
- NIST – National Institute of Standards and Technology
- CRMLN – Cholesterol Reference Method Laboratory Network
- SRM – Standard Reference Material
- CRM – Certified Reference Material

The calibration and value assignment processes are in compliance with EN ISO 17511, Metrological Traceability of Values Assigned to Calibrators and Control Materials.

The measured analytes in the MetLyte 8 are traceable to the following reference materials or methods. The Piccolo Xpress Analysis System controls and calibration verification materials are validated for use only with the Piccolo Xpress Analysis System and assigned values may not be commutable with other methods. For specific analyte reference standard methods, refer to Section 3. Principles of Method.

Analyte	Calibration Standard	Method
CL	Correlation to Beckman LX-20 / DX-20	Enzymatic
CK	IFCC	Enzymatic
GLU	NIST SRM #909	Enzymatic
K+	NIST SRM #909	Enzymatic
NA+	Correlation to Beckman LX-20 / DX-20	Enzymatic
tCO2	Correlation to Beckman LX-20 / DX-20	Enzymatic
BUN	NIST SRM #912A	Enzymatic

**Quality Control**

See Section 6 (Calibration and Quality Control) of the Piccolo Xpress Operator’s Manual. Performance of the Piccolo Xpress chemistry analyzer can be verified by running controls. For a list of approved quality control materials with acceptance ranges, please contact Abaxis Technical Support. Other human serum or plasma-based controls may not be compatible. Quality control materials should be stored as per the package-insert included with the controls.

If control results are out of range, repeat one time. If still out of range, call Abaxis Technical Support. Do not report results if controls are outside their labeled limits. See the Piccolo Xpress chemistry analyzer Operator’s Manual for a detailed discussion on running, recording, interpreting, and plotting control results.

**Waived Laboratories (US only):** Abaxis recommends control testing as follows:

- at least every 30 days
- whenever the laboratory conditions have changed significantly, e.g. Piccolo moved to a new location or changes in temperature control
- when training or retraining of personnel is indicated
- with each new lot (CLIA waived tests in waived status labs)

**Non-Waived Laboratories (US only):** Abaxis recommends control testing to follow federal, state, and local guidelines.

And the non-waived ones will use the below:

- Performance of the Piccolo Xpress chemistry analyzer can be verified by running controls. For a list of approved quality control materials with acceptance ranges, please contact Abaxis Technical Support. Other human serum or plasma-based controls may not be compatible. Quality control materials should be stored as per the package-insert included with the controls.



- If control results are out of range, repeat one time. If still out of range, call Abaxis Technical Support. Do not report results if controls are outside their labeled limits. See the Piccolo Xpress chemistry analyzer Operator's Manual for a detailed discussion on running, recording, interpreting, and plotting control results.

## 9. Results

The Piccolo Xpress chemistry analyzer automatically calculates and prints the analyte concentrations in the sample. Details of the endpoint and rate reaction calculations are found in the Piccolo Xpress chemistry analyzer Operator's Manual.

Interpretation of results is detailed in the Operator's Manual. Results are printed onto result cards or paper rolls supplied by Abaxis. The result cards or paper rolls have an adhesive backing for easy placement in the patient's files.

The reaction for each analyte occurs at 37°C (98.6°F).

## 10. Limitations of Procedure

General procedural limitations are discussed in the Piccolo Xpress chemistry analyzer Operator's Manual.

- The only anticoagulant **recommended for use** with the Piccolo Xpress chemistry analyzer System is **lithium heparin**. Abaxis has performed studies demonstrating that EDTA, fluoride, oxalate and any anticoagulant containing ammonium ions will interfere with at least one chemistry contained in the Piccolo MetLyte 8 Panel. Do not use sodium heparin.
- Samples with hematocrits in excess of 62% packed red cell volume (a volume fraction of 0.62) may give inaccurate results. Samples with high hematocrits may be reported as hemolyzed. These samples may be spun down to get plasma then re-run in a new reagent disc.
- **Any result for a particular test that exceeds the assay range should be analyzed by another approved test method or sent to a referral laboratory. Do not dilute the sample and run it again on the Piccolo Xpress chemistry analyzer .**

**Warning:** Extensive testing of the Piccolo Xpress chemistry analyzer system has shown that, in very rare instances, sample dispensed into the reagent disc may not flow smoothly into the sample chamber. Due to the uneven flow, an inadequate quantity of sample may be analyzed and several results may fall outside the reference ranges. The sample may be re-run using a new reagent disc.

**Note:** Operators shall report any serious incident that has occurred in relation to the device to the manufacturer.

### Interference

Substances were tested as interferents with the analytes. Human serum pools were prepared. The concentration at which each potential interferent was tested was based on the testing levels in CLSI EP7-P.<sup>41</sup>

### Effects of Endogenous Substances

- Physiological interferents (hemolysis, icterus and lipemia) cause changes in the reported concentrations of some analytes. The sample indices are printed on the bottom of each printout to inform the operator about the levels of interferents present in each sample.
- The Piccolo Xpress chemistry analyzer suppresses any results that are affected by >10% interference from hemolysis, lipemia or icterus. "HEM", "LIP", or "ICT" respectively, is printed on the printout in place of the result.
- Extremely elevated amylase levels (>9,000 U/L) will have a significant effect, >10% increase, on the chloride result. The concentration of amylase is not evaluated by the Piccolo system for each specimen.
- The potassium assay in the Piccolo system is a coupled pyruvate kinase (PK) / lactate dehydrogenase (LDH) assay. Therefore, in cases of extreme muscle trauma or highly elevated levels of creatine kinase (CK), the Piccolo may recover a falsely elevated potassium(K+) value. In such cases, unexpected high potassium recoveries need to be confirmed utilizing a different methodology.
- For maximum levels of endogenous substances contact Abaxis Technical Support.

### Effects of Exogenous and Therapeutic Substances

Thirty-five exogenous and therapeutic substances were selected as potential interferents for Abaxis test methods based on recommendations by Young.<sup>42</sup> Significant interference is defined as greater than  $\pm 10\%$  shift in the result for a normal range specimen. Human serum pools were supplemented with known concentrations of the drugs or chemicals and then analyzed. **Please see Table 2 for a list of exogenous and therapeutic substances evaluated. Please see Table 3 for a list of analytes where interference was observed.**

**Table 2: Exogenous and Therapeutic Substances Evaluated**

Potential Interferent	Highest Concentration Tested (mg/dL unless otherwise specified)
Acetaminophen	100
Acetoacetate	102
Acetylsalicylic Acid	50
Ampicillin	30
Ascorbic acid	20
Caffeine	10
Calcium chloride	20
Cephalothin (Keflin)	400
Chloramphenicol	100
Cimetidine	16
Dopamine	19
Epinephrine	1
Erythromycin	10
Glutathione	30
Hydrochlorothiazide	7.5
Ibuprofen	50
Isoniazide	4
$\alpha$ -Ketoglutarate	5
Ketoprofen	50
L-dopa	5
Lidocaine	1
Lithium Lactate	84
Methicillin	100
Methotrexate	0.5
Metronidazole	5
Nafcillin	1
Nitrofurantoin	20
Oxacillin	1
Oxaloacetate	132
Penicillin G	100
Phenytoin (5,5-Diphenylhydantion)	3
Proline	4
Pyruvate	44
Rifampin	0.5
Salicylic Acid	50
Sulfasalazine	150
Sulfanilamide	50
Theophylline	20

Please see Table 3 for a list of analyses where interference was observed.

**Table 3: The following substances showed greater than  $\pm 10\%$  shift in the result for a normal range specimen.**

	Concentration Which Produces > 10% Interference
<b>Creatine Kinase</b>	
Cephalothin	400
Dopamine	15
L-dopa	5
Methotextrate	0.5
Nitrofurantoin	20
<b>Creatinine</b>	
Ascorbic acid	20
Dopamine	19
L-dopa	5
Epinephrine	1
Glutathione	30
<b>Glucose</b>	
Oxaloacetate	132
Pyruvate	44
<b>Potassium</b>	
Penicillin G	100
Sulfasalazine	150
<b>Sodium</b>	
Cephalothin	400
Methotrexate	0.5
Penicillin G	100
<b>Total Carbon Dioxide</b>	
Acetaminophen	100
Ascorbic Acid	20
Cephalothin	400
Cimetidine	16
Erythromycin	10
Lidocaine	1
Methotrexate	0.5
Nitrofurantoin	20
Salicylic Acid	50
Sulfasalazine	150

- For the Chloride assay, bromide at toxic levels ( $\geq 15$  mmol/L) can cause a significant effect ( $> 10\%$  increase), on the chloride result. Iodide at very high concentrations (30 mmol/L, highest level tested) has no effect. Normal physiological levels of bromide and iodide do not interfere with the Piccolo Chloride Test System.

## 11. Expected Values

Samples from 125-150 adult males and females were analyzed to determine the reference interval for the electrolytes. These ranges were calculated based on the 95% reference interval estimated from the combined (overall) values obtained from the reference subjects.<sup>43</sup> These intervals are provided as a guideline only. It is recommended that your office or institution establish normal ranges for your particular patient population.

**Table 4: Piccolo Reference Intervals\***

Analyte	Common Units	SI Units
<b>Chloride</b>	98-108 mmol/L	98-108 mmol/L
<b>Creatine Kinase (Female)</b>	30-190 U/L	30-190 U/L
<b>Creatine Kinase (Male)</b>	39-380 U/L	39-380 U/L
<b>Creatinine</b>	0.6-1.2 mg/dL	53-106 µmol/L
<b>Glucose</b>	73-118 mg/dL	4.1-6.6 mmol/L
<b>Potassium</b>	3.6-5.1 mmol/L	3.6-5.1 mmol/L
<b>Sodium</b>	128-145 mmol/L	128-145 mmol/L
<b>Total Carbon Dioxide</b>	18-33 mmol/L	18-33 mmol/L
<b>Blood Urea Nitrogen (BUN)</b>	7-22 mg/dL	2.5-7.9 mmol urea/L

\*Data was generated using equivalence device Piccolo Blood Chemistry Analyzer.

## 12. Performance Characteristics

### Linearity

The chemistry for each analyte is linear over the dynamic range listed below when the Piccolo Xpress chemistry analyzer is operated according to the recommended procedure (refer to the Piccolo Xpress chemistry analyzer Operator's Manual).

**Table 5: Piccolo Dynamic Ranges**

Analyte	Common Units	SI Units
<b>Chloride</b>	80-135 mmol/L	80-135 mmol/L
<b>Creatine Kinase</b>	5-5,000 U/L	5-5,000 U/L
<b>Creatinine</b>	0.2-20 mg/dL	18-1768 µmol/L
<b>Glucose</b>	10-700 mg/dL	0.6-38.9 mmol/L
<b>Potassium</b>	1.5-8.5 mmol/L	1.5-8.5 mmol/L
<b>Sodium</b>	110-170 mmol/L	110-170 mmol/L
<b>Total Carbon Dioxide</b>	5-40 mmol/L	5-40 mmol/L
<b>Blood Urea Nitrogen (BUN)</b>	2-180 mg/dL	0.7-64.3 mmol/urea/L

If the analyte concentration is above the measuring range (dynamic range), but less than the system range, the printout will indicate a ">" sign at the upper limit and an asterisk after the number, e.g. ALT >2000\* U/L. If lower than the dynamic range, a "<" will be printed with an asterisk, e.g. ALT <5\* U/L. For values that are grossly beyond the measurement range (system range), "~~~" will be printed instead of a result. Any time "~~~" appears on a printout, collect a new sample and rerun the test. If results for the second sample are suppressed again, please call Abaxis Technical Support.

### Sensitivity (Limits of Detection)

The lower limit of the reportable (dynamic) range for each analyte is: chloride 80 mmol/L; creatine kinase 5 U/L; creatinine 0.2 mg/dL (18 µmol/L); glucose 10 mg/dL (0.6 mmol/L) potassium 1.5 mmol/L; sodium 110 mmol/L; total carbon dioxide 5 mmol/L; and blood urea nitrogen 2.0 mg/dL (0.7 mmol urea/L).

### Precision

Precision studies were conducted using CLSI EP5-A guidelines<sup>44</sup> with modifications based on CLSI EP18-P<sup>45</sup> for unit-use devices. Results for within-run and total precision were determined using two levels of commercially available control materials and in the case of potassium two levels of plasma pools. The studies made use of multiple instruments and two reagent disc lots. Creatine kinase, creatinine, glucose, sodium and urea nitrogen testing was performed at one site; potassium and total carbon dioxide testing was performed at two sites over 20 days; chloride testing was done at two sites over a period of five days. Potassium testing was conducted at a CLIA

waived site making use of three analyzers, one lot of reagent discs, and two operators over five days.

Results of precision studies are shown in Table 6.

**Table 6: Precision**

Analyte	Sample Size	Within-Run	Total
<b>Chloride (mmol/L)</b>	N = 160		
<u>Control 1</u>			
Mean		97.8	97.8
SD		1.63	1.74
CV		1.7	1.7
<u>Control 2</u>			
Mean		113.6	113.6
SD		1.97	2.22
CV		1.7	2.0
<b>Creatine Kinase (U/L)</b>	N = 120		
<u>Control 1</u>			
Mean		134	134
SD		2.7	2.7
CV		2.0	2.0
<u>Control 2</u>			
Mean		526	526
SD		7.7	7.7
CV		1.5	2.0
<b>Creatinine (mg/dL)</b>	N=80		
<u>Control 1</u>			
Mean		1.1	1.1
SD		0.14	0.14
CV		12.5	13.1
<u>Control 2</u>			
Mean		5.2	5.2
SD		0.23	0.27
CV		4.4	5.2
<b>Glucose (mg/dL)</b>	N=80		
<u>Control 1</u>			
Mean		66	66
SD		0.76	1.03
CV		1.1	1.6
<u>Control 2</u>			

**Table 6: Precision (continued)**

Analyte	Sample Size	Within-Run	Total
Mean		278	278
SD		2.47	3.84
CV		0.9	1.4
<b>Potassium (mmol/L)</b>	N = 150		
<u>Control 1</u>			
Mean		3.2	3.2
SD		0.09	0.11
CV		2.8	3.3
<u>Control 2</u>	N = 149		
Mean		6.2	6.2
SD		0.09	0.10
CV		1.4	1.7
Plasma Pool 1	N=150		
Mean		3.2	3.2
SD		0.07	0.09
CV		2.3	2.9
Plasma Pool 2	N=150		
Mean		5.4	5.4
SD		0.09	0.10
CV		1.6	1.9
<b>Sodium (mmol/L)</b>	N = 80		
<u>Control 1</u>			
Mean		143.5	143.5
SD		2.28	2.28
CV		1.6	1.6
<u>Control 2</u>			
Mean		120.0	120.0
SD		2.13	2.13
CV		1.8	1.8
<b>Total Carbon</b>			
<b>Dioxide (mmol/L)</b>	N = 120		
<u>Control 1</u>			
Mean		21.4	21.4
SD		2.29	2.29
CV		10.7	10.7
<u>Control 2</u>			

**Table 6: Precision (continued)**

Analyte	Sample Size	Within-Run	Total
Mean		10.5	10.5
SD		0.90	0.90
CV		8.6	8.6
Blood Urea Nitrogen (mg/dL)	N = 80		
<u>Control 1</u>			
Mean		19	19
SD		0.35	0.40
CV		1.9	2.1
<u>Control 2</u>			
Mean		65	65
SD		1.06	1.18
CV		1.6	1.8

**Whole Blood Precision for Potassium**

Whole blood precision was tested at a CLIA waived site by two CLIA waiver operators. The study used four Piccolo Xpress Analyzers with 16 replicates per sample for four (4) fresh, lithium heparin whole blood samples.

**Table 7: Whole Blood Precision for Potassium**

Potassium (mmol/L)	Sample Size	Within-Run	Total
Whole Blood 1	N = 16		
Mean		3.9	3.9
SD		0.06	0.11
CV		1.6	2.8
Whole Blood 2	N = 16		
Mean		4.0	4.0
SD		0.11	0.14
CV		2.9	3.4
Whole Blood 3	N = 16		
Mean		4.0	4.0
SD		0.11	0.15
CV		2.8	3.9
Whole Blood 4	N = 16		
Mean		4.0	4.0
SD		0.11	0.13
CV		2.7	3.4

### Correlation

Heparinized whole blood and serum samples were collected and assayed by a comparative method(s) for creatine kinase, creatinine, glucose, potassium, sodium, total carbon dioxide and urea nitrogen. The whole blood samples were analyzed at the field sites and the serum samples were analyzed by comparative methods. In some cases, high and low supplemented samples were used to cover the dynamic range.

Representative correlation statistics are shown in Table 8.

**Table 8: Correlation with Comparative Method(s)\*\***

	Correlation Coefficient	Slope	Intercept	SEE	N	Sample Range (mmol/L)	Comparative Method
<b>Chloride</b> (mmol/L)	0.978	0.982	-1.1	1.84	120	71-118	Vitros 950
<b>Creatine Kinase</b> (U/L)	0.967	1.194	-25	9.05	47	6-813	Cobas Fara®
<b>Creatinine</b> (mg/dL)	0.993	0.926	0.0	0.15	260	0.4-14.7	Paramax®
	0.987	0.866	0.1	0.16	107	0.4-7.5	Beckman
<b>Glucose</b> (mg/dL)	0.987	1.009	-2.8	3.89	251	72-422	Paramax®
	0.997	0.943	1.2	4.69	91	56-646	Beckman
<b>Potassium</b> (mmol/L) Whole Blood (Waived laboratory)	0.984	0.99	0.13	0.10	130	1.3-9.5	Siemens VISTA Plasma
<b>Potassium</b> (mmol/L) Whole Blood (moderately complex laboratory)	0.984	0.98	0.12	0.18	178	1.5-8.6	Siemens VISTA Serum
<b>Potassium</b> (mmol/L) Serum (moderately complex laboratory)	0.990	0.98	0.06	0.14	178	1.4-8.5	Siemens VISTA Serum
<b>Sodium</b> (mmol/L)	0.937	0.782	27.7	3.79	113	116-154	Radiometer KNA™ 2
<b>Total Carbon Dioxide</b> (mmol/L)	0.947	0.903	2.4	0.84	60	6-39	Cobas Fara
<b>Blood Urea Nitrogen</b> (mg/dL)	0.964	0.923	0.5	1.08	251	6-52	Paramax®
	0.983	0.946	0.0	0.66	92	6-38	Beckman

\* Serum samples from hospitalized patients provided a broader, and possibly more useful, sample range than did venous whole blood samples from out-patients. Correlation statistics for the Piccolo calcium test are from these serum samples.

\*\*Data was generated using equivalence device Piccolo Blood Chemistry Analyzer.

It should be noted that serum will typically give higher results for K+ compared to whole blood or plasma for physiological reasons. The variation can range from approximately 0.2 to 0.9mmol/L and is dependent on a number of factors. The primary effect is dependent upon the number of blood cells present in the patient sample.<sup>48,49</sup>



### Results of Untrained User Study

An “untrained user” study was conducted in which participants were given only the test instructions and asked to perform testing of 3 discs with blinded randomized samples. The samples consisted of serum pools prepared at three levels for each of the eight analytes, chloride, creatine kinase, creatinine, glucose, potassium, sodium, total carbon dioxide, and blood urea nitrogen (BUN). The participants were not given any training on the use of the test or instrument. A total of 62 participants were enrolled from 3 sites, representing a diverse demographic (educational, age, gender, etc) population.

Tables below present the summary of the performance for each analyte.

#### Chloride (CL<sup>-</sup>)

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	93	105	115
Mean value By Piccolo (mmol/L)	94.6	106	115.5
SD	1.66	1.5	1.74
%CV	1.8	1.4	1.5
Observed Range	90 – 100	102 - 108	110 - 119

#### Creatine Kinase (CK)

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	121	308	746
Mean value By Piccolo (U/L)	119.0	308.0	745.6
SD	4.9	6.2	11.2
%CV	4.1	2.0	1.5
Observed Range	110 – 131	291 – 234	718 – 771

#### Creatinine (CRE)

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	79.56	185.64	609.96
Mean value By Piccolo (µmol/L)	78.68	182.99	609.08
SD	8.84	8.84	9.72
%CV	11.2%	4.8%	1.6%
Observed Range	61.88 – 106.08	159.12 – 203.32	574.6 – 636.48

#### Glucose

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	5.33	7.27	20.15
Mean value By Piccolo (mmol/L)	5.28	7.23	20.31
SD	0.06	0.07	0.16
%CV	1.1%	1.0%	0.8%
Observed Range	5.16 – 5.44	6.94 – 7.38	19.48 – 20.71

**Potassium (K<sup>+</sup>)**

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	3.4	5.6	7.2
Mean value By Piccolo (mmol/L)	3.42	5.66	7.19
SD	0.11	0.14	0.14
%CV	3.3	2.5	1.9
Observed Range	3.2 – 3.7	5.2 – 5.9	6.7 – 7.5

**Sodium (NA<sup>+</sup>)**

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	122	141	158
Mean value By Piccolo (mmol/L)	122.1	140.8	157.5
SD	1.25	1.15	1.63
%CV	1.0	0.8	1.0
Observed Range	118 - 127	138 - 143	154 - 162

**Total Carbon Dioxide (tCO<sub>2</sub>)**

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	21	28	33
Mean value By Piccolo (mmol/L)	20.3	27.6	34.4
SD	1.03	1.26	1.27
%CV	5.1	4.6	3.7
Observed Range	18 – 23	23 - 30	32 - 38

**Blood Urea Nitrogen (BUN)**

	Level 1	Level 2	Level 3
Number	62	62	62
Target Concentration	5.36	15.0	25.7
Mean value By Piccolo (mg/dL)	5.39	14.64	25,78
SD	0.35	0.36	0.46
%CV	2.3%	2.5%	1.8%
Observed Range	5.0 – 5.71	13.21 – 15.35	24.28 – 26.78

### 13. Symbols



Use By



Catalog Number



Batch Code



In Vitro Diagnostic  
Medical Device



Consult Instructions  
for Use



Manufacturer



Do Not Reuse



X Number of Test  
Devices In Kit



Manufacturing  
Sequence



Serial Number



Authorized  
Representative  
in the European  
Community



Temperature  
Limitation



Caution

PN:  
Part Number



denotes conformity to specified  
European directives

## 14. Bibliography

1. Ono T, et al. A new enzymatic assay of chloride in serum. *Clin Chem* 1988;34:552-3.
2. Kuby SA, Noda, L and Lardy HA. Adenosinetriphosphate-Creatine Transphosphorylase. *J Biol Chem* 1954; 209: 191-201.
3. Tanzer MI And Gilvarg C. Creatine And Creatine Kinase Measurement. *J Biol Chem* 1959; 234:3201-3204.
4. Nuttall FQ And Wedin DS. A Simple Rapid Colorimetric Method For Determination Of Creatine Kinase Activity. *J Lab Clin Med* 1966;68:324-332.
5. Oliver IT. 1955 A Spectrophotometric Method For The Determination Of Creatine Phosphokinase And Myokinase. *Biochem J* 1955;61:116-122.
6. Rosalki SB.. An Improved Procedure Or Serum Creatine Phosphokinase Determination. *J Lab Clin Med* 1967;69:696-705.
7. Szasz G, Gruber W And Bernt E. Creatine Kinase In Serum: I. Determination Of Optimum Reaction Conditions. *Clin Chem* 1976;22: 650-656.
8. Expert Panel On Enzymes, Committee Of Standards (IFCC). 1979 Approval Recommendations Of IFCC Methods For The Measurement Of Catalytic Concentrations Of Enzymes, Part 1. General Considerations. *Clin Chim Acta*, IFCC Sections: 98: 163-174.
9. Committee On Enzymes Of The Scandinavian Society For Clinical Chemistry And Clinical Physiology. 1976. Recommended Method For The Determination Of Creatine Kinase In Blood. *Scand J. Clin Lab Invest* 36: 711-723.
10. Knoll VE, et al. Spezifische Kreatininbetimmung Im Serum. *Z Klin Chemi Clin Biochem.* 1970;8:582-587.
11. Haeckel R, et al. Simplified Determinations of the "True" Creatinine Concentration In Serum And Urine. *J Cklin Chem Clin Biochem.* 1980;18:385-394.
12. Moss GA, et al. Kinetic Enzymatic Method For Determining Serum Creatinine. 1975;21:1422-1426.
13. Jaynes PK, et al. An Enzymatic, Reaction-Rate Assay For Serum Creatinine With a Centrifugal Analyzer. 1982; 28:114-117.
14. Fossati P, et al. Enzymatic Creatinine Assay: A New Colorimetric Method Based on Hydrogen Peroxide Measurement. 1983;29:1494-1496.
15. Whelton A, et al. Nitrogen Metabolites and Renal Function. In:CA Burtis and ER Ashwood, Eds., *Tietz Textbook of Clinical Chemistry*, 2<sup>nd</sup> Ed. Philadelphia: W.B. Saunders Company. 1994; 1513-1575.
16. Folin O, et al. A system of blood analysis. *J Biol Chem.* 1919;38:81-110.
17. Somogyi M. A reagent for the copper-iodometric determination of very small amounts of sugar. *J Biol Chem.* 1937;117:771-776.
18. Nelson N, et al. A photometric adaption of the Somogyi method for the determination of glucose. *J Biol.* 1944; 153:375-380.
19. Kaplan LA. Glucose. In:LA Kaplan and AJ Pesce, eds., *Clinical Chemistry: Theory, Analysis, and Correlation*, 2<sup>nd</sup> ed St. Louis: The C.V. Mosby Company;1989;pp.850-856.
20. Berry MN, et al. Enzymatic determination of potassium in serum. *Clin Chem* 1989;35:817-20.
21. Van Pelt J. Enzymatic determination of sodium, potassium and chloride in serum compared with determination by flame photometry, coulometry and ion selective electrodes. *Clin Chem* 1994;40:846-7.
22. Hubl W, et al. Enzymatic determination of sodium, potassium and chloride in abnormal (hemolyzed, icteric, lipemic, paraproteinemic, or uremic) serum samples compared with indirect determination with ion selective electrodes. *Clin Chem* 1994;40:1528-31.
23. Helgerson RC, et al. Host-guest Complexation. 50. Potassium and sodium ion-selective chromogenic ionophores. *J Amer Chem Soc* 1989;111:6339-50.
24. Kumar A, et al. Chromogenic ionophore-based methods for spectrophotometric assay of sodium and potassium in serum and plasma. *Clin Chem* 1988;34:1709-12.
25. Berry MN, et al. Enzymatic determination of sodium in serum. *Clin Chem* 1988;34:2295-8.
26. Skeggs LT Jr. An automatic method for the determination of carbon dioxide in blood plasma. *Am J. Clin Pathol* 1960;33:181-5.
27. Korzun WJ, Miller WG. Carbon Dioxide. In: Kaplan LA, Pesce AJ, eds. *Clinical chemistry theory, analysis and correlation*, 2<sup>nd</sup> ed. St. Louis: The CV Mosby Company, 1989:869-72.
28. Fales FW. Urea in serum, direct diacetyl monoxide method. In:WR Faulkner and S Meites, eds., *Selected Methods of Clinical Chemistry*, vol 9. Washington, DC.: American Association for Clinical Chemistry;1982;pp.365-373.
29. Van Slyke, et al. A permanent preparation of urease, and its use in the determination of urea. *J Biol Chem*, 1914; 19:211-228.
30. Fawcett JK, et al. A rapid and Precise method for the determination of urea. *J Clin Pathol*, 1960;13:156-159.
31. Chaney, et al. Urea and ammonia determinations. *Clin Chem*, 1962;8:130-132.
32. Talke H, et al. Enzymatische Harnstoffbestimmung in Blut and Serum im optischen Test nach Warburg. *Klin Wochensh*, 1965;43:174-175.

33. Hallett, et al. Reduced nicotinamide adenine dinucleotide-coupled reaction for emergency blood urea estimation. *Clin Chim Acta*, 1971;35:33-37.
34. Patton, et al. Spectrophotometric and kinetics investigation of the Berthelot reaction for the determination of ammonia. *Anal Chem*, 1977;49:464-469.
35. Sampson EJ, et al. A coupled-enzyme equilibrium method for the measuring urea in serum: optimization and evaluation of the AACC study group on Urea Candidate reference method. *Clin Chem*, 1980;26:816-826.
36. CLSI. Physician's office laboratory guidelines, tentative guideline, 2<sup>nd</sup> ed. CLSI Document POL1-T2. Wayne, PA: CLSI, 1992.
37. Scott, M.G. Electrolytes and Blood Gases. In: Burtis CA, Ashwood ER, eds. *Tietz Textbook of Clinical Chemistry*. 3<sup>rd</sup> ed. Philadelphia: WB Saunders Company. 1999:1058-9.
38. CLSI. Procedures for the handling and processing of blood specimens; tentative standard. CLSI Document H18-T. Wayne, PA: CLSI, 1984.
39. Rehak NN, Chiang BT. Storage of whole blood: effect of temperature on the measured concentration of analytes in serum. *Clin Chem* 1988; 34:2111-4.
40. Scott, M.G. Electrolytes and Blood Gases. In: Burtis CA, Ashwood ER, eds. *Tietz Textbook of Clinical Chemistry*. 3<sup>rd</sup> ed. Philadelphia: WB Saunders Company, 1999: 1065-6.
41. CLSI. Interference testing in clinical chemistry; proposed guideline. CLSI Document EP7-P. Wayne, PA: CLSI, 1986.
42. Young DS. *Effects of drugs on clinical laboratory tests*, 3<sup>rd</sup> ed. Washington, DC: AACC Press, 1990.
43. CLSI. How to define and determine reference intervals in the clinical laboratory, approved guidelines, 2<sup>nd</sup> ed. CLSI Document C28-A2. Wayne, PA: CLSI, 2000.
44. CLSI. Evaluation of precision performance of clinical chemistry devices; approved guideline. CLSI Document EP5-A. Wayne, PA: CLSI, 1999.
45. CLSI. Quality management for unit-use testing; proposed guideline. CLSI Document EP18-P. Wayne, PA: CLSI, 1999.
46. CLSI. Method comparison and bias estimation using patient samples; approved guideline. CLSI Document EP9-A. Wayne, PA: CLSI, 1995.
47. Overfield CV, et al. Glycolysis: a re-evaluation of the effect on blood glucose. *Clin Chim Acta*. 1972; 39: 35-40.
48. Hartland AJ, Hartland JH, Neary RN. Serum Potassium Is Unreliable as an Estimate of in Vivo Plasma Potassium. *Clin Chem* 1999;45:1091-1092.